Zevra Therapeutics (ZVRA) EBT Margin (2019 - 2026)

Zevra Therapeutics (ZVRA) has 8 years of EBT Margin data on file, last reported at 123.7% in Q1 2026.

• Quarterly EBT Margin rose 13310.0% year-over-year to 123.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 109.04% (up 29510.0% YoY) and the FY2025 annual result came in at 81.41%, up 46317.0% from the prior year.
• EBT Margin rose to 123.7% in Q1 2026, from 37.07% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 297.15% in Q2 2025 to a low of 1751.76% in Q2 2022.
• A 5-year average of 289.18% and a median of 161.76% in 2023 frame the typical range for EBT Margin.
• Annual changes were most pronounced in 2022 — EBT Margin plunged 180351 bps — and 2023, when it jumped 172051 bps.
• Tracing ZVRA's EBT Margin over 5 years: stood at 148.66% in 2022, then decreased by 4 bps to 153.96% in 2023, then retreated by 10 bps to 169.56% in 2024, then soared by 122 bps to 37.07% in 2025, then jumped by 234 bps to 123.7% in 2026.
• The last three EBT Margin figures came in at 123.7% (Q1 2026), 37.07% (Q4 2025), and 3.75% (Q3 2025), per Business Quant data.